{"id":62735,"date":"2026-04-09T20:43:10","date_gmt":"2026-04-09T12:43:10","guid":{"rendered":"https:\/\/flcube.com\/?p=62735"},"modified":"2026-04-09T20:43:12","modified_gmt":"2026-04-09T12:43:12","slug":"sino-biopharm-wins-fda-approval-for-pan-kras-inhibitor-tqb3205-first-in-human-trial-in-advanced-malignancies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62735","title":{"rendered":"Sino Biopharm Wins FDA Approval for Pan\u2011KRAS Inhibitor TQB3205 \u2013 First\u2011in\u2011Human Trial in Advanced Malignancies"},"content":{"rendered":"\n<p><strong>Sino Biopharmaceutical Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG:\u202f1177<\/a>) announced that the <strong>US Food and Drug Administration (FDA)<\/strong> has granted <strong>clinical trial approval<\/strong> for <strong>TQB3205<\/strong>, a <strong>pan\u2011KRAS inhibitor<\/strong>, enabling initiation of <strong>first\u2011in\u2011human studies<\/strong> in patients with <strong>advanced malignant tumors<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>US FDA<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Investigational New Drug (IND) \/ Clinical Trial Approval<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>TQB3205 (pan\u2011KRAS inhibitor)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced malignant tumors (pan\u2011tumor)<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>First\u2011in\u2011human (FIH)<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>Sino Biopharm&#8217;s entry into global KRAS inhibitor race<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> <strong>Pan\u2011KRAS<\/strong> \u2013 Multiple KRAS mutant proteins (G12C, G12D, G12V, etc.)<\/li>\n\n\n\n<li><strong>Binding Mode:<\/strong> <strong>High\u2011affinity<\/strong> non\u2011covalent binding, locking KRAS in <strong>inactive GDP\u2011bound state<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Blocks downstream oncogenic signaling pathways:<\/li>\n\n\n\n<li><strong>MAPK pathway<\/strong> (RAF\u2011MEK\u2011ERK cascade)<\/li>\n\n\n\n<li><strong>PI3K\u2011AKT pathway<\/strong> (survival\/metabolism)<\/li>\n\n\n\n<li><strong>Clinical Advantage:<\/strong> Broad mutant coverage vs. single\u2011mutation inhibitors (G12C\u2011only); potential to address <strong>~25% of all cancers<\/strong> driven by diverse KRAS mutations<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Asset<\/th><th>KRAS Coverage<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>Sino Biopharm<\/strong><\/td><td><strong>TQB3205<\/strong><\/td><td><strong>Pan\u2011KRAS<\/strong><\/td><td><strong>FDA IND approved Apr\u202f2026<\/strong><\/td><\/tr><tr><td>Revolution Medicines<\/td><td>RMC\u20116236<\/td><td>Pan\u2011KRAS<\/td><td>Phase\u202fI\/II (clinical)<\/td><\/tr><tr><td>Mirati \/ BMS<\/td><td>MRTX1133<\/td><td>Pan\u2011KRAS (G12D\u2011focused)<\/td><td>Phase\u202fI\/II (clinical)<\/td><\/tr><tr><td>Amgen \/ Mirati<\/td><td>Sotorasib<\/td><td>G12C only<\/td><td>Marketed (limited scope)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>KRAS Market Opportunity:<\/strong> KRAS mutations present in <strong>~25% of all tumors<\/strong>; pan\u2011KRAS approach addresses <strong>80%+ of KRAS\u2011driven cancers<\/strong> vs. ~15% for G12C\u2011specific agents.<\/li>\n\n\n\n<li><strong>Global Expansion Strategy:<\/strong> FDA approval marks Sino Biopharm&#8217;s <strong>first US\u2011based oncology IND<\/strong>, signaling international clinical ambitions beyond Greater China.<\/li>\n\n\n\n<li><strong>Trial Timeline:<\/strong> Phase\u202fI dose\u2011escalation expected to initiate <strong>Q2\u2011Q3 2026<\/strong> in US sites; preliminary efficacy data anticipated <strong>2027<\/strong>.<\/li>\n\n\n\n<li><strong>Valuation Impact:<\/strong> Pan\u2011KRAS assets command <strong>US$1\u20115\u202fbillion<\/strong> pre\u2011proof\u2011of\u2011concept valuations; successful early data could trigger major partnership or M&amp;A interest.<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Addressable market for pan\u2011KRAS inhibitors estimated at <strong>US$15\u201120\u202fbillion<\/strong> globally by 2035, spanning lung, pancreatic, colorectal, and other solid tumors.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical trial initiation, therapeutic potential, and commercial prospects for TQB3205. Actual results may differ due to risks including safety failures, efficacy limitations, competitive pressure, and regulatory setbacks.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026040900050_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026040900050_c.\"><\/object><a id=\"wp-block-file--media-93a57d9c-200b-4c42-b401-35a9bc03c167\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026040900050_c.pdf\">2026040900050_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026040900050_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-93a57d9c-200b-4c42-b401-35a9bc03c167\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sino Biopharmaceutical Ltd (HKG:\u202f1177) announced that the US Food and Drug Administration (FDA) has granted&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,908,71,313],"class_list":["post-62735","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-hkg-1177","tag-nmpa-fda-filing","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sino Biopharm Wins FDA Approval for Pan\u2011KRAS Inhibitor TQB3205 \u2013 First\u2011in\u2011Human Trial in Advanced Malignancies - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sino Biopharmaceutical Ltd (HKG:\u202f1177) announced that the US Food and Drug Administration (FDA) has granted clinical trial approval for TQB3205, a pan\u2011KRAS inhibitor, enabling initiation of first\u2011in\u2011human studies in patients with advanced malignant tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62735\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino Biopharm Wins FDA Approval for Pan\u2011KRAS Inhibitor TQB3205 \u2013 First\u2011in\u2011Human Trial in Advanced Malignancies\" \/>\n<meta property=\"og:description\" content=\"Sino Biopharmaceutical Ltd (HKG:\u202f1177) announced that the US Food and Drug Administration (FDA) has granted clinical trial approval for TQB3205, a pan\u2011KRAS inhibitor, enabling initiation of first\u2011in\u2011human studies in patients with advanced malignant tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62735\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-09T12:43:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-09T12:43:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62735#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62735\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino Biopharm Wins FDA Approval for Pan\u2011KRAS Inhibitor TQB3205 \u2013 First\u2011in\u2011Human Trial in Advanced Malignancies\",\"datePublished\":\"2026-04-09T12:43:10+00:00\",\"dateModified\":\"2026-04-09T12:43:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62735\"},\"wordCount\":375,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"HKG: 1177\",\"NMPA &amp; FDA Filing\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62735#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62735\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62735\",\"name\":\"Sino Biopharm Wins FDA Approval for Pan\u2011KRAS Inhibitor TQB3205 \u2013 First\u2011in\u2011Human Trial in Advanced Malignancies - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-09T12:43:10+00:00\",\"dateModified\":\"2026-04-09T12:43:12+00:00\",\"description\":\"Sino Biopharmaceutical Ltd (HKG:\u202f1177) announced that the US Food and Drug Administration (FDA) has granted clinical trial approval for TQB3205, a pan\u2011KRAS inhibitor, enabling initiation of first\u2011in\u2011human studies in patients with advanced malignant tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62735#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62735\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62735#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino Biopharm Wins FDA Approval for Pan\u2011KRAS Inhibitor TQB3205 \u2013 First\u2011in\u2011Human Trial in Advanced Malignancies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino Biopharm Wins FDA Approval for Pan\u2011KRAS Inhibitor TQB3205 \u2013 First\u2011in\u2011Human Trial in Advanced Malignancies - Insight, China&#039;s Pharmaceutical Industry","description":"Sino Biopharmaceutical Ltd (HKG:\u202f1177) announced that the US Food and Drug Administration (FDA) has granted clinical trial approval for TQB3205, a pan\u2011KRAS inhibitor, enabling initiation of first\u2011in\u2011human studies in patients with advanced malignant tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62735","og_locale":"en_US","og_type":"article","og_title":"Sino Biopharm Wins FDA Approval for Pan\u2011KRAS Inhibitor TQB3205 \u2013 First\u2011in\u2011Human Trial in Advanced Malignancies","og_description":"Sino Biopharmaceutical Ltd (HKG:\u202f1177) announced that the US Food and Drug Administration (FDA) has granted clinical trial approval for TQB3205, a pan\u2011KRAS inhibitor, enabling initiation of first\u2011in\u2011human studies in patients with advanced malignant tumors.","og_url":"https:\/\/flcube.com\/?p=62735","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-09T12:43:10+00:00","article_modified_time":"2026-04-09T12:43:12+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62735#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62735"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino Biopharm Wins FDA Approval for Pan\u2011KRAS Inhibitor TQB3205 \u2013 First\u2011in\u2011Human Trial in Advanced Malignancies","datePublished":"2026-04-09T12:43:10+00:00","dateModified":"2026-04-09T12:43:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62735"},"wordCount":375,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Clinical trial approval \/ initiation","HKG: 1177","NMPA &amp; FDA Filing","Sino Biopharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62735#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62735","url":"https:\/\/flcube.com\/?p=62735","name":"Sino Biopharm Wins FDA Approval for Pan\u2011KRAS Inhibitor TQB3205 \u2013 First\u2011in\u2011Human Trial in Advanced Malignancies - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-09T12:43:10+00:00","dateModified":"2026-04-09T12:43:12+00:00","description":"Sino Biopharmaceutical Ltd (HKG:\u202f1177) announced that the US Food and Drug Administration (FDA) has granted clinical trial approval for TQB3205, a pan\u2011KRAS inhibitor, enabling initiation of first\u2011in\u2011human studies in patients with advanced malignant tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62735#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62735"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62735#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino Biopharm Wins FDA Approval for Pan\u2011KRAS Inhibitor TQB3205 \u2013 First\u2011in\u2011Human Trial in Advanced Malignancies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62735"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62735\/revisions"}],"predecessor-version":[{"id":62737,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62735\/revisions\/62737"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}